Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

EVP, Chief Strategy Officer of Abbvie Inc (30-Year

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
cooler Member Profile
 
Followed By 6
Posts 636
Boards Moderated 0
Alias Born 08/25/05
160x600 placeholder
Form 8.3 - Allergan Plc Dow Jones News - 1/20/2020 9:09:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 1/17/2020 9:41:00 AM
Form 8.3 - [Allergan PLC] Dow Jones News - 1/16/2020 9:21:00 AM
Form 8.3 - [Allergan plc] Dow Jones News - 1/15/2020 10:05:00 AM
Form 8.3 - [Abbvie. Inc] Dow Jones News - 1/15/2020 10:01:00 AM
AbbVie Shares Up; Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study Dow Jones News - 1/14/2020 12:22:00 PM
Form 8.3 - Allergan Plc Dow Jones News - 1/14/2020 10:44:00 AM
AbbVie: Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study Dow Jones News - 1/14/2020 9:37:00 AM
New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Rank... PR Newswire (US) - 1/14/2020 8:45:00 AM
AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary PR Newswire (Canada) - 1/14/2020 5:30:00 AM
Form 8.3 - Allergan Plc Dow Jones News - 1/13/2020 9:26:00 AM
AbbVie to Host Fourth-Quarter and Full-Year 2019 Earnings Conference Call PR Newswire (US) - 1/13/2020 8:00:00 AM
EU Grants Conditional Approval to AbbVie-Allergan $63 Billion Deal Dow Jones News - 1/10/2020 10:14:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 1/10/2020 9:52:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 1/9/2020 9:50:00 AM
Form 8.3 - Allergan Plc Dow Jones News - 1/8/2020 10:25:00 AM
AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition PR Newswire (US) - 1/8/2020 8:00:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 1/7/2020 10:04:00 AM
AbbVie Gets Canada OK for Rinvoq in Adults With Rheumatoid Arthritis Dow Jones News - 1/7/2020 8:50:00 AM
AbbVie reçoit l'approbation de Santé Canada pour l'emploi de RINVOQ® (upadacitinib), un médicament à prise orale pour le... PR Newswire (Canada) - 1/7/2020 8:01:00 AM
AbbVie Receives Health Canada Approval of RINVOQ® (upadacitinib), an Oral Medication for the Treatment of Adults with Modera... PR Newswire (Canada) - 1/7/2020 8:01:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 1/6/2020 10:03:00 AM
Form 8.3 - [ Allergan plc] Dow Jones News - 1/3/2020 9:40:00 AM
AbbVie to Present at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire (US) - 1/3/2020 8:00:00 AM
Drug Prices Climb by 5.8% on Average, Less Than Last Year Dow Jones News - 1/2/2020 4:26:00 PM
cooler   Thursday, 08/01/19 04:13:20 PM
Re: None
Post # of 517 
EVP, Chief Strategy Officer of Abbvie Inc (30-Year Financial, Insider Trades) Henry O Gosebruch (insider trades) bought 30,000 shares of ABBV on 07/29/2019 at an average price of $67.28 a share. The total cost of this purchase was $2 million.

https://finance.yahoo.com/news/abbvie-inc-abbv-evp-chief-221505814.html


Was hoping it would go back into the 60's. I was willing to buy it in the low 70's so I picked up more today.

cooler


.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist